Format

Send to

Choose Destination
J Exp Med. 2008 Feb 18;205(2):271-4. doi: 10.1084/jem.20080167. Epub 2008 Feb 11.

An antidote for Staphylococcus aureus pneumonia?

Author information

1
Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA. fdeleo@niaid.nih.gov

Erratum in

  • J Exp Med. 2008 Mar 17;205(3):739.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against alpha-hemolysin (Hla), a cytolytic toxin secreted by most S. aureus strains, protects mice against lethal pneumonia. This finding represents the first successful vaccine strategy for the treatment of staphylococcal pneumonia.

PMID:
18268043
PMCID:
PMC2271020
DOI:
10.1084/jem.20080167
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center